Efficacy and Safety of Bortezomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Chun-yan Sun¹¶, Jun-ying Li¹¶, Zhang-bo Chu¹, Lu Zhang¹, Lei Chen¹, Yu Hu¹*

¹ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

* Corresponding author

E-mail: dr_huyu@126.com (Y.H.)

¶These authors contributed equally to this work.
Abstract

Multiple myeloma (MM) is a B-cell neoplasm with a high incidence of relapse. Bortezomib has been extensively studied for the maintenance treatment of MM. Here we carried out a meta-analysis to determine the efficacy and safety of maintenance therapy with bortezomib. We searched for clinical trials in PubMed (Medline), Embase (OVID) and the Cochrane Library. Two randomized controlled trials (RCTs) enrolling a total of 1338 patients were included. Bortezomib maintenance statistically significantly improved both PFS (HR 0.67, 95% CI = 0.51 to 0.87, P = 0.003) and OS (HR= 0.75 therapy, 95% CI = 0.63 to 0.89, P = 0.001) more than did non-bortezomib maintenance therapy. Our analysis revealed higher incidence of neutropenia (RR = 1.39; 95% CI=1.08 to 1.79), peripheral neuropathy (RR = 2.23; 95% CI= 1.38 to 3.61, P=0.001) and cardiologic events (RR = 1.91; 95% CI= 1.12 to 3.28, P=0.02) in patients with bortezomib maintenance therapy. Our meta-analysis demonstrates OS and PFS benefits of bortezomib maintenance therapy in patients with newly diagnosed MM. However, the therapy is associated with increased risk of adverse events. Additionally, more RCTs are needed for better understanding and determination of optimal bortezomib maintenance therapy in MM.

Introduction

Multiple myeloma (MM), a disease results from a proliferation of plasma cells and thus characterized by an elevation in immunoglobulin, is the second most frequent hematologic malignancy around the world. The median age at diagnosis is 70 years, with 37% of them younger than 65 years old, 26% aged from 65 to 74 years, and 37% beyond 75 years. The incidence rates in men are higher than in women [1, 2]. The application of high dose therapy (HDT) and autologous stem cell transplantation (ASCT) as well as the advent of novel agents (e.g. immunomodulatory drugs including thalidomide and lenalidomide, and the proteasome inhibitor bortezomib) improve survival in MM but the disease still remains incurable due to high incidence of relapse. Therefore, MM maintenance therapy, a treatment given for a specified duration to maintain the response of first-line therapy and prolong survival [3], is of great interest to clinical and translational researchers.

Early trials incorporating conventional chemotherapy, interferon, or glucocorticosteroids into maintenance therapy failed to show satisfactory results due to limited survival benefit or toxicity [4]. Three meta-analyses evaluating thalidomide maintenance therapy showed progression-free survival and overall survival benefits in transplantation-eligible patients [5, 6]. However, thalidomide maintenance has several limitations, including the toxic risk of peripheral neuropathy, shorter overall survival in patients with high-risk cytogenetics [7] and less obvious improvement in overall survival (OS) for elderly patients [8-11]. Clinical trials using another immunomodulatory drug lenalidomide for maintenance therapy showed effectiveness in response rates and progression-free survival (PFS), but also treatment-related adverse events and potential risk of SPMs (second primary malignancies) [12, 13].

Bortezomib is a boronic-acid based reversible proteasome inhibitor involving in the ubiquitin–proteasome pathway of cellular protein homeostasis. Disruption of proteasome activity results in cell growth arrest and apoptosis. Malignant plasma cells in MM produce large amount of immunoglobulins and have higher levels of proteasome activity compared with normal cells. Therefore, MM cells are more sensitive to the pro-apoptotic effects of proteasome inhibition than normal cells [14, 15]. Bortezomib-based induction therapy has already shown improved PFS and OS, even for those patients with t (4; 14) or renal failure [16, 17], and therefore is recommended for both transplantation-eligible and transplantation-ineligible newly diagnosed MM patients [18]. This leads to further investigation for incorporating bortezomib into maintenance phase. To obtain a better understanding of the efficacy and safety of bortezomib-based maintenance therapy in newly diagnosed MM patients, we carried out this meta-analysis.
Results

Selection of studies

We identified 498 publications through initial search and kept 22 of them for further full-text review after title and abstract screening. 19 publications were excluded after full-text review and only 3 articles [23-25] were remained to our final analysis. It is noted that two articles [24, 25] providing important data from one trial were considered as one in our analysis. A phase III PETHEMA/GEM randomized trial comparing patients who received maintenance therapy after induction and ASCT with either interferon-alpha or thalidomide or thalidomide plus bortezomib was included at the beginning but excluded at last due to lack of sufficient data for analysis [28]. Therefore, finally two RCTs were included in the present meta-analysis (Fig 1).

The characteristics of the two trials are summarized in Table 1. One study published in 2014 was conducted at 61 centers in Italy from May 2006 to January 2009 [23]. A total of 511 newly diagnosed myeloma patients who were not candidates for high-dose therapy plus stem-cell transplantation (age > 65 years or with coexisting comorbidities) were randomly assigned to receive VMPT (melphalan, prednisone, bortezomib, thalidomide) induction-VT (bortezomib, thalidomide) maintenance (254 patients) or VMP (melphalan, prednisone, bortezomib) induction-no maintenance (257 patients ) therapy for two years. The median age is 71 years and median follow-up time is 54 months. The other study, conducted by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the German Multicenter Myeloma Group (GMMG), was published in 2012 as full- text, and its extended follow-up was reported as abstract in 2013 [24, 25]. A total of 827 eligible, newly diagnosed, symptomatic MM patients were randomly assigned to VAD (vincristine, doxorubicin, dexamethasone) induction-intensification with HDM and ASCT-thalidomide maintenance (arm A , 414 patients) or PAD (bortezomib, doxorubicin, and dexamethasone) induction -intensification with HDM and ASCT- bortezomib maintenance for 2 years (arm B , 413 patients). The median age is 57 years and median follow-up time is 67 months.

The methodological quality of the included studies is shown in table 2 with Jadad scale. Additionally, both studies applied ITT analysis (intention to treat) and neither of them offered any information about allocation concealment.

Efficacy

The pooled HR of PFS was 0.67 (95% CI = 0.51 to 0.87, P = 0.003), indicating a trend of PFS improvement with bortezomib maintenance. However, there was a significant heterogeneity between the two trials (P = 0.05, I^2 = 74%, Fig 2). The pooled HR of OS shows the bortezomib maintenance therapy arm is superior (HR= 0.75, 95% CI = 0.63 to 0.89, P = 0.001). No significant heterogeneity was revealed between the two trials (P = 0.56, I^2 = 0%, Fig 3)

Safety

Both trials have reported the incidence of adverse events. So we carried out a meta-analysis measuring pooled risk ratios (RR) to compare grade 3-4 adverse events in bortezomib maintenance therapy arm and non-bortezomib maintenance therapy arm. The analysis revealed significant differences between the two arms and the bortezomib maintenance therapy statistically showed significantly increased risk for developing neutropenia (RR = 1.39; 95% CI=1.08 to 1.79), peripheral neuropathy (RR = 2.23; 95% CI= 1.38 to 3.61, P=0.001) and cardiologic events (RR = 1.91; 95% CI= 1.12 to 3.28, P=0.02) (Fig 4). We did not observe a significant difference in the risk of developing anemia, thrombocytopenia, infection, deep vein thrombosis and GI (gastrointestinal) symptoms between the two arms. No evidence of significant heterogeneity was revealed between the two trials.

Discussion

During the past decade, bortezomib has been shown to have great benefit in induction therapy of MM patients, thus leading to further clinical trials incorporating bortezomib into maintenance therapy. The
objective of an ideal maintenance therapy is to improve PFS and OS with minimal toxicity and without interfering patients’ quality of life [3]. Therefore, we carried out this meta-analysis to evaluate the efficacy and safety of bortezomib maintenance in MM.

Two RCTs with a total of 1338 patients were included in our analysis. Both significant PFS and OS improvement were seen in our pooled results with bortezomib maintenance over non-bortezomib maintenance therapy. This result indicates the benefit of bortezomib during maintenance in MM patients. Notably, according to an analysis of PFS calculated from the time of last HDM in HOVON-65/GMMG-HD4 trial, a significant difference in favor of the PAD arm was observed, indicating that although post-transplantation bortezomib and thalidomide both achieved response upgrades, bortezomib contributed more to improvement of PFS [24]. It is noted that a significant heterogeneity exists when calculating the pooled HR results of PFS. We considered that the heterogeneity comes from several sources. Firstly, the different characteristics of individual patients in two studies could affect the evaluated results, including age, coexisting comorbidities or MM severity. Secondly, both the induction and maintenance regimes differed between the two studies. Furthermore, we should take measurement bias into consideration.

Regarding the safety of applying bortezomib during maintenance, our analysis revealed significant differences between the two arms. Higher incidence of neutropenia, cardiologic events, and peripheral neuropathy (PN) were observed in patients of the bortezomib maintenance group. Consistent with previous reports, peripheral neuropathy is the most frequent adverse effect, which could be managed by dose adjustment, subcutaneous administration and decreasing the frequency of administration of bortezomib [26, 27]. As for supplementary specification, newly developed grade 3 to 4 PN occurred in 8% of patients during thalidomide maintenance and 5% of patients during bortezomib in HOVON-65/GMMG-HD4 trial, and for VMPT-VT arm in the study of Palumbo, A. et al. containing both bortezomib and thalidomide during maintenance the incidence of peripheral neuropathy was 11% [23, 24].

However, conflicting results have also been reported in other studies. A phase III PETHEMA/GEM randomized trial compared bortezomib/thalidomide, thalidomide, and Alfa2b-interferon as maintenance therapy after stem-cell transplantation for multiple myeloma patients for a median follow-up of 34.9 months. The results showed that the PFS was significantly longer with TV compared with the other two arms (p=0.0009), but there was no significant difference in OS among the three arms [28]. In the UPFRONT study with patients’ median age higher than 70 years comparing VD, VTD and VMP induction followed by bortezomib maintenance, only 5% of patients experienced grade ≥3 PN during maintenance, without adverse influence on patients’ quality of life [29, 30].

In addition, the GEM2005MAS65 randomized trial investigated by the Spanish myeloma group compared maintenance therapy with bortezomib plus thalidomide (VT) or prednisone (VP) in elderly untreated myeloma patients, who had previously received induction with bortezomib, melphalan and prednisone or bortezomib, thalidomide and prednisone. The results showed an increase in CR rate, remarkably long PFS, and acceptable toxicity, suggesting clinical benefit of bortezomib-based maintenance therapy [31]. Another analysis of the phase III HOVON-65/GMMG-HD4 trial showed that the known adverse impact of deletion 17p (del17p13) can be markedly reduced by incorporating bortezomib into the treatment and may be important for the long-term management of patients with this high-risk feature [32].

In view of the facts mentioned above, we suggest that more RCTs are needed to help us further understand the efficacy and safety of bortezomib maintenance in MM with different characteristics of patients and diverse drug combination regimes.

Our analysis was carried out through a standardized process, but it also has some limitations. Firstly, only two studies were included in our analysis after comprehensive search and careful selection. One study without sufficient data was excluded [28]. Secondly, possible publication bias can affect our interpretation. Thirdly, the Italian study didn’t report proper techniques for randomized allocation. And in both studies, randomized allocation were applied only before induction but not maintenance therapy, which led to difficulty making a clear dissection of the role of bortezomib maintenance therapy. Fourthly, due to the paucity of studies, we couldn't perform a sensitivity analysis. In addition, variant characteristics of patients
enrolled in the two RCTs, different study designs and varied length of follow-up time may also influence the statistical power of pooled outcomes.

In conclusion, our meta-analysis showed significant overall survival and progression free survival benefits of bortezomib maintenance therapy in patients with newly diagnosed MM. However, the increased risk of adverse events warrants serious consideration and adequate measures. Future RCTs are needed for better understanding and optimizing bortezomib maintenance therapy in MM.

**Method**

**Article Inclusion/Exclusion Criteria and Quality**

We searched for clinical trials in PubMed (Medline), Embase (OVID), and the Cochrane Library using key words “myeloma”, “bortezomib OR Velcade” and “maintenance OR consolidation OR continuous therapy OR continuous treatment”. To identify eligible studies that may have been missed during the initial online search, we further examined the reference lists of relevant reviews and trials identified. The last search dated back to November 2015.

Two investigators independently reviewed all the titles and abstracts obtained from the above search strategy. Potentially related articles were then checked in full text to identify phase III randomized controlled trials (RCTs) that compared the outcomes of bortezomib-based and non-bortezomib-based maintenance therapies in newly diagnosed MM patients. Included studies were required to report PFS (progression-free survival) and OS (overall survival). Duplicated studies were regarded as one.

Two investigators independently evaluated the methodological quality (i.e. the randomization, blinding method and completeness of follow-up) of the included studies using the Jadad scale, which could show us intuitive results by giving each study a score. Score 3-5 and 0-2 were associated with high and low quality, respectively [19]. Additionally, we checked if these studies had adopted ITT analysis (intention to treat) and reported allocation concealment, considering the neglect in Jadad scale [20].

**Statistical Analysis**

Revman software (5.3) was used to perform all calculations related to meta-analysis. Progression-free survival (PFS) was measured from the date of randomization to the time of disease progression, relapse, or death. Overall survival (OS) was calculated as the time from randomization until death from any cause. We used hazard ratio (HR) with 95% confidence interval (95% CI) of OS and PFS outcomes for the bortezomib maintenance treatment arm over the non-bortezomib treatment arm to evaluate the efficacy. Dichotomous outcomes about adverse effects were evaluated using risks ratios (RR) with 95% confidence intervals. Pooled results of HR and RR were calculated based on the inverse variance (IV) method and the Mantel-Haenszel (M-H) method, respectively. Statistical heterogeneity was assessed using the $I^2$ test and the DerSimonian and Laird random effects model was applied when heterogeneity was significant ($I^2 > 50\%$) [21, 22]. The publication bias assessment was not formally carried out due to limited number of included trials.

**References**


Author Contributions

C.Y.S, J.Y.L and Y. H designed this meta-analysis. C.Y.S and J.Y.L conducted it and wrote the main manuscript text. J.Y.L, Z. B.C, L.Z, and L.C prepared all the figures. All authors reviewed the manuscript.

Additional Information

Competing Financial Interests Statement

The author(s) declare no competing financial interests.

Financial Disclosure

This analysis was supported by

1. National Natural Science Foundation of China (No. 81272625), received by Dr. Chun-yan Sun.

2. National Natural Science Funds for Youth Science Fund Project (No. 81302042), received by Dr. Chun-yan Sun.
3. Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST, received by Pro. Yu Hu.


The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Figures**

Fig 1. Flow diagram of study selection

Fig 2. Pooled hazard ratios (HR) of progression-free survival (PFS) comparing bortezomib maintenance therapy arm with non-bortezomib maintenance therapy arm.

Fig 3. Pooled hazard ratios (HR) of overall survival (OS) comparing bortezomib maintenance therapy arm with non-bortezomib maintenance therapy arm.

Fig 4. Pooled risk ratios (RR) of grade 3-4 adverse events comparing bortezomib maintenance therapy arm with non-bortezomib maintenance therapy arm. (a) neutropenia (b) thrombocytopenia (c) anemia (d) infection (e) deep vein thrombosis (f) peripheral neuropathy (g) cardiologic events (h) GI symptoms

**Tables**

<table>
<thead>
<tr>
<th>Study</th>
<th>People</th>
<th>N</th>
<th>Maintenance therapy regimen</th>
<th>Planned maintenance duration</th>
<th>Median follow-up</th>
<th>Median PFS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>eligable, newly diagnosed, symptomatic MM</td>
<td>827</td>
<td>Arm A (n=414): daily thalidomide 50 mg</td>
<td>2 years</td>
<td>67 months</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>median age: 57</td>
<td></td>
<td>Arm B (n=413): 2-weekly bortezomib 1.3 mg/m² i.v.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sonneveld P. 2013</td>
<td>(HOVON-65/GMMG-HD4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palumbo A. 2014</td>
<td>(Italy)</td>
<td>511</td>
<td>VT (n=254); No maintenance (n=257)</td>
<td>2 years</td>
<td>54 months</td>
<td>VMPT-VT: 35.3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VMP: 24.8 months</td>
</tr>
</tbody>
</table>

**Table 1. Characteristics of studies included in the meta-analysis**

HDM: high-dose melphalan; ASCT: autologous stem cell transplant; VT: bortezomib at a dose of 1.3 mg/m² every 15 days and thalidomide at a dose of 50 mg per day; VMP: bortezomib-melphalan-prednisone; VMPT-VT: bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide; N/A: not available.
<table>
<thead>
<tr>
<th>study</th>
<th>Randomization</th>
<th>Blinding</th>
<th>lost/Withdrawal to follow-up</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sonneveld P. 2013 (HOVON-65/GMMG-HD4)</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Palumbo A. 2014 (Italy)</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 2. Quality score of included studies applying Jadad scale
Search for potentially relevant articles in PubMed (Medline), Embase (OVID), The Cochrane Library and remove duplicated articles

N=498

Articles excluded after screening titles and abstracts (N =476)
Review/Guideline/Editorial (N=254)
Non-relevant (N=57)
Unsuitable Trials (N=114)
Case reports (N=41)
Basic research articles (N=10)

Articles for full text view
N=22

Articles excluded (N=19)
Duplication (N=15)
Unsuitable trial (N=1)
Without essential detailed result data (N=3)

3 articles (2 RCTs) finally included (1 in abstracts and 2 in full-text)
N =2
<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>log(Hazard Ratio)</th>
<th>SE</th>
<th>Weight</th>
<th>IV Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palumbo A. 2014</td>
<td>-0.5447</td>
<td>0.1073</td>
<td>47.4%</td>
<td>0.58 [0.47, 0.72]</td>
</tr>
<tr>
<td>Sonneveld P. 2013</td>
<td>-0.2744</td>
<td>0.0877</td>
<td>52.6%</td>
<td>0.76 [0.64, 0.90]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.67 [0.51, 0.87]</td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.03; \text{Chi}^2 = 3.80, df = 1 (P = 0.05); I^2 = 74\%$

Test for overall effect: $Z = 2.98 (P = 0.003)$
Study or Subgroup | log[Hazard Ratio] | SE | Weight | IV, Fixed, 95% CI | Hazard Ratio
---|---|---|---|---|---
Palumbo A. 2014 | -0.3567 | 0.1517 | 34.0% | 0.70 [0.52, 0.94]
Sonneveld P. 2013 | -0.2485 | 0.109 | 66.0% | 0.78 [0.63, 0.97]

Total (95% CI) | 100.0% | 0.75 [0.63, 0.89]

Heterogeneity: Chi² = 0.34, df = 1 (P = 0.56); I² = 0%
Test for overall effect: Z = 3.22 (P = 0.001)
<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>bortezomib</th>
<th>non-bortezomib</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H. Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palumbo A. 2014</td>
<td>25</td>
<td>250</td>
<td>57</td>
<td>0.92</td>
<td>1.11 [0.76, 1.67]</td>
</tr>
<tr>
<td>Sonneveld P. 2013</td>
<td>8</td>
<td>413</td>
<td>49</td>
<td>0.87</td>
<td>1.15 [0.42, 3.13]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>33</td>
<td>32</td>
<td>65</td>
<td>1.04</td>
<td>1.33 [0.91, 1.93]</td>
</tr>
</tbody>
</table>

Test for overall effect: Z = 1.07 (P = 0.29)

- **Neutropenia**

- **Thrombocytopenia**

- **Anemia**

- **Infection**

- **Deep vein thrombosis**

- **Peripheral neuropathy**

- **Cardiovascular events**

- **Gastrointestinal symptoms**